# A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

> **NCT07226362** · PHASE1 · COMPLETED · sponsor: **Aspeya Switzerland SA** · enrollment: 44 (actual)

## Conditions studied

- Safety, and Tolerability

## Interventions

- **COMBINATION_PRODUCT:** DHE inhalation powder low dose administered via dry powder inhaler (DPI) device
- **COMBINATION_PRODUCT:** DHE inhalation powder high dose administered via dry powder inhaler (DPI) device
- **DRUG:** DHE injected intravenously (1 mg)
- **DRUG:** DHE 2 mg administered by nasal spray (Migranal®)
- **DRUG:** Metoclopramide 10mg

## Key facts

- **NCT ID:** NCT07226362
- **Lead sponsor:** Aspeya Switzerland SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-09
- **Primary completion:** 2025-10-02
- **Final completion:** 2025-10-02
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226362, "A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07226362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*